成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜,MDA-MB-231
  • MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜,MDA-MB-231

MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜

價格 詢價
包裝 1000000細(xì)胞數(shù) 2000000細(xì)胞數(shù)
最小起訂量 1000000細(xì)胞數(shù)
發(fā)貨地 上海
更新日期 2025-04-05
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱:MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜英文名稱:MDA-MB-231
品牌: ATCC\RCB等產(chǎn)地: 國外
保存條件: 常溫培養(yǎng)或液氮凍存純度規(guī)格: MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜
產(chǎn)品類別: 化學(xué)試劑
種屬: 詳見產(chǎn)品資料組織: 詳見產(chǎn)品資料
細(xì)胞系: 詳見產(chǎn)品資料細(xì)胞形態(tài): 詳見產(chǎn)品資料
生長狀態(tài): 詳見產(chǎn)品資料靶點: 詳見產(chǎn)品資料
應(yīng)用: 詳見產(chǎn)品資料
2025-04-05 MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜 MDA-MB-231 1000000細(xì)胞數(shù)/RMB;2000000細(xì)胞數(shù)/RMB ATCC\RCB等 國外 常溫培養(yǎng)或液氮凍存 MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜 化學(xué)試劑

"MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜

傳代比例:1:2-1:4(首次傳代建議1:2)

生長特性:貼壁生長

細(xì)胞系的應(yīng)用:1)免疫組化研究2)RNA干擾研究3)藥物作用研究4)慢病毒轉(zhuǎn)染研究等其它應(yīng)用。細(xì)胞系通常用于實驗研究,如增殖、遷移、侵襲等。細(xì)胞系在多個領(lǐng)域的研究中被廣泛應(yīng)用,包括基礎(chǔ)醫(yī)學(xué)、臨床試驗、藥物篩選和分子生物學(xué)研究。這些研究不僅在中國,也在日本、美國和歐洲等多個國家和地區(qū)進(jìn)行。

換液周期:每周2-3次

U2OS Cells;背景說明:骨肉瘤;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:Hela-Ap-1細(xì)胞、BIU-87細(xì)胞、KLN-205細(xì)胞

CEMO-1 Cells;背景說明:急性B淋巴細(xì)胞白血?。荒行?傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:懸浮;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:HCC-1395細(xì)胞、MADB 106細(xì)胞、NUGC-3細(xì)胞

L6 Cells;背景說明:該細(xì)胞是Yaffe在甲基膽蒽存在的情況下從大鼠大腿肌原代培養(yǎng)的最初兩代細(xì)胞中分離得到的;在培養(yǎng)基中融合形成多核的肌管和橫紋肌纖維,細(xì)胞融合的程度隨著代數(shù)的增加而下降,因此細(xì)胞應(yīng)低代次冷凍并周期性地重新克隆以選擇融合能力強(qiáng)的細(xì)胞。鼠痘病毒陰性。該細(xì)胞應(yīng)在達(dá)匯合狀態(tài)前傳代,以延緩細(xì)胞分化能力的喪失。;傳代方法:1:2傳代;生長特性:貼壁生長;形態(tài)特性:成肌細(xì)胞樣;相關(guān)產(chǎn)品有:SKCO 1細(xì)胞、DU4475細(xì)胞、Michigan Cancer Foundation-12F細(xì)胞

背景信息:-MB-231來自患有轉(zhuǎn)移乳腺腺癌的51歲女病人的胸水。在裸鼠和ALS處理的BALB/c小鼠中,它能形成低分化腺癌(III級)。

MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜

產(chǎn)品包裝:復(fù)蘇發(fā)貨:T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨:1ml凍存管(兩支)

公司細(xì)胞系主要引進(jìn)ATCC、DSMZ、JCRB、KCLB、RIKEN、ECACC等細(xì)胞庫,細(xì)胞系體外培養(yǎng),它們會成長為單層細(xì)胞,附著或緊貼在培養(yǎng)瓶上,或懸浮在體外的溶液中,細(xì)胞系復(fù)蘇周期短,公司細(xì)胞系狀態(tài)良好,飽滿,有光澤等優(yōu)點。EDTA的作用:許多人不用胰酶,只用EDTA,或者用胰酶/EDTA聯(lián)合作用。這里要明白,胰酶切割細(xì)胞外基質(zhì)的一些負(fù)責(zé)粘連和附著的蛋白,而EDTA通過螯合Ca離子,作用于整聯(lián)蛋白的活性,所以EDTA的作用更加溫和。有的人在胰酶里添加一些EDTA,或者對付特別難消化的細(xì)胞,添加多一些EDTA,就是這個道理。一般不要試圖延長消化時間(如果10min還消化不下來的話),而應(yīng)該想其它辦法。

HEK 293A Cells;背景說明:胚腎;腺病毒包裝;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:ESC-410細(xì)胞、LC-1/sq細(xì)胞、RGC5細(xì)胞

NCI/ADR-RES Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:FM-88細(xì)胞、DC 2.4細(xì)胞、L-cell細(xì)胞

GM637 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:OCI-Ly19細(xì)胞、DMS273細(xì)胞、H865細(xì)胞

45.6.3.1 Cells(提供STR鑒定圖譜)

來源說明:細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

物種來源:人源、鼠源等其它物種來源

MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜

形態(tài)特性:上皮細(xì)胞樣

細(xì)胞復(fù)蘇相關(guān)注意事項:1.取細(xì)胞的過程中注意帶HAO防凍手套,護(hù)目鏡。此項尤為重要,細(xì)胞凍存管可能漏入,解凍時凍存管中的氣溫急劇上升,可導(dǎo)致爆炸。2.凍存的問題:凍存的配置已是常識,在這里不作詳述,但二甲基亞砜(DMSO )對細(xì)胞不是完全無毒副作用,在常溫下,二甲基亞砜對細(xì)胞的毒副作較大,因此,必須在1-2min內(nèi)使凍存完全融化。如果復(fù)蘇溫度太慢,會造成細(xì)胞的損傷,二甲基亞砜(DMSO)ZuiHAO選擇進(jìn)口產(chǎn)品。3.離心前須加入少量培養(yǎng)。細(xì)胞解凍后二甲基亞砜濃度較GAO,注意加入少量培養(yǎng)可稀釋其濃度,以減少對細(xì)胞的損傷。4.離心問題:目前主要有兩種見解。一種是解凍后的細(xì)胞懸直接吹打均勻后分裝到培養(yǎng)瓶中進(jìn)行培養(yǎng),第二天換。因為離心的目的是兩個,去除DMSO,去除死細(xì)胞,這個是標(biāo)準(zhǔn)流程,但對一般人來說,把握不HAO離心轉(zhuǎn)速和時間,轉(zhuǎn)的不夠活細(xì)胞沉底的少,細(xì)胞就全被扔掉了,轉(zhuǎn)過了活細(xì)胞會受壓過大,死亡。此外在操作過程中容易污染,所以不推薦。另一種說法為細(xì)胞懸中含有二甲基亞砜(DMSO),DMSO對細(xì)胞有一定的毒副作用,所以須將離心后的體前倒凈,且一定倒干凈。我在試驗中按照常規(guī)的離心分裝的方法進(jìn)行復(fù)蘇,結(jié)果無異常。5.細(xì)胞貼壁少的問題:教科書中說明凍存細(xì)胞解凍時1ml細(xì)胞要加10ml-15ml培養(yǎng),而在我的試驗中的經(jīng)驗總結(jié)為培養(yǎng)基越少細(xì)胞越容易貼附。6.復(fù)蘇細(xì)胞分裝的問題:試驗中我的經(jīng)驗總結(jié)為復(fù)蘇1管細(xì)胞一般可分裝到1-2只培養(yǎng)瓶中,分裝過多,細(xì)胞濃度過低,不利于細(xì)胞的貼壁。7.加培養(yǎng)基的量放入問題:這個量的多少的把握主要涉及到的問題DMSO的濃度,從如果你加培養(yǎng)基的太少,那么DMSO的濃度就會比較大,就會影響細(xì)胞生長,從以前的資料來看,DMSO的濃度在小于0.5%的時候?qū)σ话慵?xì)胞沒有什么影響,還有一個說法是1%。所以如果你的凍存的濃度是10%DMSO的話那么加10ml以上的培養(yǎng)基就恰HAO稀釋到了無害濃度。

H526 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:每周換液2-3次。;生長特性:懸浮生長 ;形態(tài)特性:上皮細(xì)胞;相關(guān)產(chǎn)品有:PLCPRF5細(xì)胞、HMy2.CIR細(xì)胞、GTL-16細(xì)胞

SGC-996 Cells;背景說明:膽囊癌;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:Hs 604.T細(xì)胞、HCET細(xì)胞、LAN1細(xì)胞

NCI H508 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長特性:貼壁生長;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:NB9細(xì)胞、NK-92.05細(xì)胞、J45.01細(xì)胞

H522 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:3-1:6傳代;每周換液2-3次。;生長特性:貼壁生長;形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:HUASMC細(xì)胞、JHH-2細(xì)胞、Daudi細(xì)胞

NKT Cells;背景說明:NK Cells;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:懸浮;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:MASMC細(xì)胞、Tca8113細(xì)胞、SKMEL5細(xì)胞

HuT-78 Cells;背景說明:皮膚;T淋巴瘤;男性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:懸浮;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:LLC-PK1細(xì)胞、University of Arizona Cell Culture-812細(xì)胞、LS-513細(xì)胞

NU-GC-3 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:6傳代;生長特性:貼壁生長;形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:MGC803細(xì)胞、ACCM細(xì)胞、MC 116細(xì)胞

HA1800 Cells;背景說明:星形膠質(zhì) Cells;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:HUSMC細(xì)胞、SUDHL-10細(xì)胞、K7M2-WT細(xì)胞

WEHI-231 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:NCI-H2170細(xì)胞、CCC-HPF-1細(xì)胞、SW-900細(xì)胞

hRMECs Cells;背景說明:視網(wǎng)膜微血管;內(nèi)皮 Cells;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:HSAS4細(xì)胞、LSECs細(xì)胞、NCI-H1672細(xì)胞

alpha TC1.6 Cells;背景說明:胰島素瘤;a細(xì)胞;C57BL/6xDBA/2;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:HO1N1細(xì)胞、MIN-6細(xì)胞、BC-024細(xì)胞

RFL-6 Cells;背景說明:胚肺;成纖維細(xì)胞;SD大鼠;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:SNUC2B細(xì)胞、PG13細(xì)胞、Stanford University-Diffuse Histiocytic Lymphoma-8細(xì)胞

DHL-6 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:3—1:6傳代,3—4天換液1次;生長特性:懸浮生長 ;形態(tài)特性:淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有:MLMA細(xì)胞、H719細(xì)胞、A549/DDP細(xì)胞

GTL 16 Cells;背景說明:胃癌;肝轉(zhuǎn)移;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:FO [Mouse myeloma]細(xì)胞、UPCISCC154細(xì)胞、MDAMB436細(xì)胞

CHP 126 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:H-23細(xì)胞、OVCAR.3細(xì)胞、Cates-1B細(xì)胞

C-Li-7 Cells;背景說明:人肝癌細(xì)胞株。這株細(xì)胞從裸鼠體外移植瘤中建立。;傳代方法:1:2傳代;生長特性:貼壁生長 ;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:SW-780細(xì)胞、SJSA1細(xì)胞、KU 812F細(xì)胞

C4-2 Bone metastatic Cells;背景說明:前列腺癌;左鎖骨上淋巴結(jié)轉(zhuǎn)移;男性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:H-82細(xì)胞、SW-527細(xì)胞、NBL-7細(xì)胞

68-41-Cas9 Cells(提供STR鑒定圖譜)

Abcam MCF-7 B2M KO Cells(提供STR鑒定圖譜)

ARMD1-hiPSC5 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRM201 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XST061 Cells(提供STR鑒定圖譜)

CARNAVAL Cells(提供STR鑒定圖譜)

DA00809 Cells(提供STR鑒定圖譜)

DD2606 Cells(提供STR鑒定圖譜)

GM02162 Cells(提供STR鑒定圖譜)

BJ [Human fibroblast] Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長特性:貼壁生長;形態(tài)特性:成纖維細(xì)胞樣;相關(guān)產(chǎn)品有:H-2591細(xì)胞、PGBE1細(xì)胞、JCA-1細(xì)胞

Hep2 Cells;背景說明:最初認(rèn)為這個細(xì)胞源自喉上皮癌,但隨后通過同功酶分析、HeLa標(biāo)記染色體和DNA指紋分析發(fā)現(xiàn),起源細(xì)胞已被HeLa污染。 角蛋白免疫過氧化物酶染色陽性。;傳代方法:1:2傳代;生長特性:貼壁生長;形態(tài)特性:上皮細(xì)胞樣;相關(guān)產(chǎn)品有:H-660細(xì)胞、hFOB1.19細(xì)胞、LICR-LON-HN6-R細(xì)胞

Menschliche Und Tierische Zellkulture-1 Cells;背景說明:骨髓增生異常綜合征;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:懸浮;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:NCIH1838細(xì)胞、H157細(xì)胞、SK 1細(xì)胞

KS-1 [Human glioblastoma] Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長特性:貼壁生長;形態(tài)特性:成纖維細(xì)胞;相關(guān)產(chǎn)品有:BEL 7405細(xì)胞、BC-021細(xì)胞、TE-7細(xì)胞

UWB1289 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長特性:貼壁生長 ;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:A 2780 CP細(xì)胞、Panc_05_04細(xì)胞、NCIH2081細(xì)胞

SVOG Cells;背景說明:卵巢;顆粒 Cells;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:Panc-1-P細(xì)胞、HCC94細(xì)胞、B10BR細(xì)胞

hTERTHME1 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:SK-MEL-3細(xì)胞、PaCa2細(xì)胞、LY-R細(xì)胞

Calu-6 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:消化20分鐘。1:2。5-6天長滿。;生長特性:貼壁生長;形態(tài)特性:上皮細(xì)胞;相關(guān)產(chǎn)品有:GTL-16細(xì)胞、SW-13細(xì)胞、GM06141細(xì)胞

MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜

P3-X63-Ag8-653 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:H250細(xì)胞、JKT1細(xì)胞、SJSA細(xì)胞

SW 1116 Cells;背景說明:CSAp陰性(CSAp-)。 結(jié)腸抗原3,陰性。 角蛋白免疫過氧化物酶染色陽性。 癌基因c-myc, K-ras, H-ras, myb, sis 和fos的表達(dá)呈陽性。 未檢測到癌基因N-myc和N-ras的表達(dá)。 表達(dá)腫瘤特異的核基質(zhì)蛋白CC-4,CC-5和CC-6。;傳代方法:消化3-5分鐘。1:2。3天內(nèi)可長滿。;生長特性:貼壁生長;形態(tài)特性:上皮細(xì)胞;相關(guān)產(chǎn)品有:WM239A細(xì)胞、PF382細(xì)胞、MCF-12A細(xì)胞

NK-10A Cells;背景說明:1967年,該細(xì)胞系KleinE和KleinG建系,源于一名16歲患有Burkitt's淋巴瘤的黑人男性,beta-2-微球蛋白陰性,表達(dá)EBNA,VCA,sIg。該細(xì)胞攜帶EB病毒,是一個典型的B淋巴母細(xì)胞系,可用于白血病發(fā)病機(jī)制的研究。;傳代方法:1:2傳代;生長特性:懸浮生長;形態(tài)特性:淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有:X63細(xì)胞、EFO 27細(xì)胞、LL/2(LLc1)細(xì)胞

C41 Cells;背景說明:宮頸鱗癌;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:HEK293-A細(xì)胞、C2A細(xì)胞、EMT6細(xì)胞

NCIH1648 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:3-1:6傳代;生長特性:貼壁生長;形態(tài)特性:上皮細(xì)胞;相關(guān)產(chǎn)品有:NRK-49F細(xì)胞、Hs343T細(xì)胞、NS-1細(xì)胞

SUM102 Cells;背景說明:乳腺癌;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:CPAE細(xì)胞、GS9L細(xì)胞、H2.35細(xì)胞

Metastatic Variant-522 Cells;背景說明:肺腺癌;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:NCI-H2291細(xì)胞、GH 3細(xì)胞、Granta 519細(xì)胞

GM20000 Cells(提供STR鑒定圖譜)

HAP1 IRF2BPL (-) 1 Cells(提供STR鑒定圖譜)

SKUT-1 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:4-1:12傳代,2天換液1次。;生長特性:貼壁生長;形態(tài)特性:上皮細(xì)胞;相關(guān)產(chǎn)品有:H-498細(xì)胞、Kit225細(xì)胞、Ra #1細(xì)胞

SW-626 Cells;背景說明:卵巢癌;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:Malme-3 M細(xì)胞、TALL 1細(xì)胞、SK-N-BE(2)細(xì)胞

NCI-H1954 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:TE13細(xì)胞、HUT-226細(xì)胞、PCI:SG-231細(xì)胞

H-209 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:4傳代;每周換液2次。;生長特性:懸浮生長,有少數(shù)細(xì)胞疏松貼壁;形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:253J-BV細(xì)胞、UCLA RO-81A-1細(xì)胞、KS-1 [Human glioblastoma]細(xì)胞

CHP-100 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:PC9細(xì)胞、CAL-33細(xì)胞、HPDE6c7細(xì)胞

Hepa1-6 Cells;背景說明:此細(xì)胞株源自C57/L小鼠中引發(fā)的BW7756肝癌;表達(dá)AFP、α1抗胰蛋白酶、淀粉酶;鼠痘病毒陰性。此細(xì)胞可以在無血清的培養(yǎng)基中繁殖,培養(yǎng)基成分是:DMEM,75%;Waymouth'sMAB87/3培養(yǎng)基,25%。添加3x10-8M。;傳代方法:1:2傳代;生長特性:貼壁生長;形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:Dx5細(xì)胞、CATH-a細(xì)胞、SAS細(xì)胞

G361mel Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:4傳代,2-3天換液1次。;生長特性:貼壁生長;形態(tài)特性:上皮細(xì)胞;相關(guān)產(chǎn)品有:VP 267細(xì)胞、HCC-202細(xì)胞、HPB/ALL細(xì)胞

NKT Cells;背景說明:NK Cells;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:懸浮;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:MASMC細(xì)胞、Tca8113細(xì)胞、SKMEL5細(xì)胞

HPS0947 Cells(提供STR鑒定圖譜)

JoN HDF Cells(提供STR鑒定圖譜)

MDCC-HP8 Cells(提供STR鑒定圖譜)

ND41657 Cells(提供STR鑒定圖譜)

PSFDFN714 Cells(提供STR鑒定圖譜)

UCSD041i-33-2 Cells(提供STR鑒定圖譜)

ZR-75-1 VIII-24 Cells(提供STR鑒定圖譜)

HCM-SqCC010 Cells(提供STR鑒定圖譜)

RPMI 1788 Cells;背景說明:B淋巴細(xì)胞;EBV轉(zhuǎn)化;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:懸浮;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:Ca Ski細(xì)胞、BIU-87/Adr細(xì)胞、GM637A細(xì)胞

NTERA-2/D1 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:RM-1細(xì)胞、H-520細(xì)胞、MAVER-1細(xì)胞

Hs1.Tes Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;生長特性:貼壁生長 ;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:hCMEC/D3細(xì)胞、UT7細(xì)胞、RPTEC/TERT 1細(xì)胞

CW-2 Cells;背景說明:來源于結(jié)腸癌。 CEA陽性,移植于裸鼠可成瘤。;傳代方法:消化3-5分鐘。1:2。3天內(nèi)可長滿。;生長特性:貼壁生長;形態(tài)特性:上皮細(xì)胞;相關(guān)產(chǎn)品有:NCIH2066細(xì)胞、C-4 I細(xì)胞、Rat Chondrosarcoma Swarm細(xì)胞

H-748 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:3-4天換液1次。;生長特性:懸浮生長 ;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:Mel624細(xì)胞、MARC 145細(xì)胞、SK-RC 39細(xì)胞

H-748 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:3-4天換液1次。;生長特性:懸浮生長 ;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:Mel624細(xì)胞、MARC 145細(xì)胞、SK-RC 39細(xì)胞

B16 melanoma F10 Cells;背景說明:B16-F10是B16-F0的亞系。;傳代方法:消化3-5分鐘。1:2。3天內(nèi)可長滿。;生長特性:貼壁生長;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:NCIH69細(xì)胞、OKT3細(xì)胞、EFO-27細(xì)胞

2PK3 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:NIH 3T6細(xì)胞、Lewis-Lung細(xì)胞、NTERA2D1細(xì)胞

Murine Thymic Epithelial Cell line 1 Cells;背景說明:胸腺;上皮細(xì)胞;自發(fā)永生;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:T-84細(xì)胞、Lilly Laboratories Cell-Porcine Kidney 1細(xì)胞、PA I細(xì)胞

SU.86.86 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2傳代;;生長特性:貼壁生長;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:D6P2T細(xì)胞、U031細(xì)胞、IMR90細(xì)胞

H661 Cells;背景說明:該細(xì)胞1982年建系,源自一位患有大細(xì)胞肺癌的男性的胸腔積液。該細(xì)胞角蛋白、波形蛋白陽性。;傳代方法:1:3—1:5傳代,每周換液2—3次;生長特性:貼壁生長;形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:ABC1細(xì)胞、BHK21細(xì)胞、TSUpr1細(xì)胞

H-740 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:UACC 812細(xì)胞、H-1436細(xì)胞、HNE-2細(xì)胞

LIXC-002 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:3傳代,3-4天傳1次;生長特性:貼壁生長;形態(tài)特性:上皮細(xì)胞樣;相關(guān)產(chǎn)品有:B4G12細(xì)胞、MRC9細(xì)胞、M059J細(xì)胞

Hs 822.T Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:4傳代;每周換液2-3次。;生長特性:貼壁生長;形態(tài)特性:上皮樣;相關(guān)產(chǎn)品有:SK-N-MC細(xì)胞、CV 1細(xì)胞、GCT0404細(xì)胞

PC 61 5.3 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:NE1-E6E7細(xì)胞、ST2細(xì)胞、HT 1197細(xì)胞

SMUSHi005-A Cells(提供STR鑒定圖譜)

MODE-K Cells;背景說明:小腸;上皮 Cells;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:RC-4B細(xì)胞、GM03190A細(xì)胞、H-69細(xì)胞

GA-10(Clone 4) Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:每周換液兩次;生長特性:懸浮生長 ;形態(tài)特性:淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有:hTERTHME1細(xì)胞、UCH1細(xì)胞、MKN-45細(xì)胞

HEL-92-1-7 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:每周2-3次。;生長特性:懸浮生長;形態(tài)特性:成淋巴細(xì)胞;相關(guān)產(chǎn)品有:HCC-70細(xì)胞、Panc-3_27細(xì)胞、BNL.1ME A.7R.1細(xì)胞

NCTC 929 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:Panc02.03細(xì)胞、HPMEC細(xì)胞、S3 HeLa細(xì)胞

Hs 695.T Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:4傳代,2-3天換液1次。;生長特性:貼壁生長;形態(tài)特性:上皮細(xì)胞;相關(guān)產(chǎn)品有:HSC6細(xì)胞、IBRS-2細(xì)胞、CHL-11細(xì)胞

SupT1 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:2-3天換液1次。;生長特性:懸浮生長;形態(tài)特性:淋巴母細(xì)胞樣 ;相關(guān)產(chǎn)品有:HB611細(xì)胞、HCC1171細(xì)胞、H4-IIE-C3細(xì)胞

EFM-192A Cells;背景說明:乳腺癌;胸腔積液轉(zhuǎn)移;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:H524細(xì)胞、Anip 973細(xì)胞、Mv1Lu細(xì)胞

MF2059 Cells;背景說明:皮膚;T淋巴細(xì)胞瘤;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:懸浮;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:WM266mel細(xì)胞、HBL 100細(xì)胞、SU.86細(xì)胞

MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜

OVTOKO Cells;背景說明:卵巢透明細(xì)胞癌;脾轉(zhuǎn)移;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:RL-65細(xì)胞、Tn 5B1-4細(xì)胞、ketr 3細(xì)胞

TE 85 ClF-5 Cells;背景說明:骨肉瘤;女性;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:IGROV細(xì)胞、UMNSAH-DF 1細(xì)胞、DMS 79細(xì)胞

IGR.OV1 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:HT 1197細(xì)胞、ST2細(xì)胞、SEG-1細(xì)胞

G 292 Clone A 141B1 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:T-HEECs細(xì)胞、CESS細(xì)胞、SUP-T1細(xì)胞

H19-7 Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:Lilly Laboratories Cell-Monkey Kidney 2細(xì)胞、JM1細(xì)胞、BNL-HCC細(xì)胞

LCLC-103H Cells;背景說明:詳見相關(guān)文獻(xiàn)介紹;傳代方法:1:2-1:3傳代;每周換液2-3次。;生長特性:貼壁或懸浮,詳見產(chǎn)品說明書部分;形態(tài)特性:詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有:NIH 3T3細(xì)胞、NCIH747細(xì)胞、MDA-MB435細(xì)胞

BayGenomics ES cell line CSI001 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RST202 Cells(提供STR鑒定圖譜)

BTLA6.4 Cells(提供STR鑒定圖譜)

L2-10C1 Cells(提供STR鑒定圖譜)

Pro104.K81.15 Cells(提供STR鑒定圖譜)

Rat-F Cells(提供STR鑒定圖譜)

" "PubMed=1000506

Lippman M.E., Bolan G., Huff K.

The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture.

Cancer Res. 36:4610-4618(1976)


PubMed=833871; DOI=10.1093/jnci/58.2.209

Fogh J., Wright W.C., Loveless J.D.

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

J. Natl. Cancer Inst. 58:209-214(1977)


PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x

Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.

Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.

Tissue Antigens 11:279-286(1978)


PubMed=730202; DOI=10.1007/BF02616120

Cailleau R.M., Olive M., Cruciger Q.V.J.

Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.

In Vitro 14:911-915(1978)


PubMed=7000337

Brinkley B.R., Beall P.T., Wible L.J., Mace M.L. Jr., Turner D.S., Cailleau R.M.

Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro.

Cancer Res. 40:3118-3129(1980)


PubMed=6935474; DOI=10.1093/jnci/66.2.239

Wright W.C., Daniels W.P., Fogh J.

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

J. Natl. Cancer Inst. 66:239-247(1981)


PubMed=7272986; DOI=10.1016/0165-4608(81)90057-1

Satya-Prakash K.L., Pathak S., Hsu T.-C., Olive M., Cailleau R.M.

Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes.

Cancer Genet. Cytogenet. 3:61-73(1981)


PubMed=7459858

Rousset M., Zweibaum A., Fogh J.

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Cancer Res. 41:1165-1170(1981)


PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)


PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)


PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)


PubMed=1961733; DOI=10.1073/pnas.88.23.10657; PMCID=PMC52989

Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S.

Mutations in p53 as potential molecular markers for human breast cancer.

Proc. Natl. Acad. Sci. U.S.A. 88:10657-10661(1991)


PubMed=7902062

de la Torre M., Hao X.-Y., Larsson R., Nygren P., Tsuruo T., Mannervik B., Bergh J.

Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases.

Anticancer Res. 13:1425-1430(1993)


DOI=10.1016/B978-0-12-333530-2.50009-5

Leibovitz A.

Cell lines from human breast.

(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994)


PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::aid-ijc10>3.0.CO;2-#

Mullen P., Ritchie A., Langdon S.P., Miller W.R.

Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.

Int. J. Cancer 67:816-820(1996)


PubMed=9815641

Wosikowski K., Schuurhuis D.H., Kops G.J.P.L., Saceda M., Bates S.E.

Altered gene expression in drug-resistant human breast cancer cells.

Clin. Cancer Res. 3:2405-2414(1997)


PubMed=9670966; DOI=10.4049/jimmunol.161.2.877

Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N., Panelli M.C., Parker K.K., Marincola F.M.

Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.

J. Immunol. 161:877-889(1998)


PubMed=9671407; DOI=10.1038/sj.onc.1201814

Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.

Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.

Oncogene 16:2865-2878(1998)


PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)


PubMed=10969801

Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.

Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.

Cancer Res. 60:4519-4525(2000)


PubMed=11499871; DOI=10.1359/jbmr.2001.16.8.1486

Yoneda T., Williams P.J., Hiraga T., Niewolna M., Nishimura R.

A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.

J. Bone Miner. Res. 16:1486-1495(2001)


PubMed=11687795; DOI=10.1038/ng754

Snijders A.M., Nowak N.J., Segraves R., Blackwood S., Brown N., Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S., Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N., Pinkel D., Albertson D.G.

Assembly of microarrays for genome-wide measurement of DNA copy number.

Nat. Genet. 29:263-264(2001)


PubMed=11697798; DOI=10.1359/jbmr.2001.16.11.2027

Peyruchaud O., Winding B., Pecheur I., Serre C.-M., Delmas P., Clezardin P.

Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.

J. Bone Miner. Res. 16:2027-2034(2001)


PubMed=12068308; DOI=10.1038/nature00766

Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)


PubMed=12353263; DOI=10.1002/gcc.10107

Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J., Mozziconacci M.-J., Conte N., Murati A., Ginestier C., Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C., Birnbaum D., Chaffanet M.

Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.

Genes Chromosomes Cancer 35:204-218(2002)


PubMed=12661003; DOI=10.1002/gcc.10196

Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., Scherneck S.

Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.

Genes Chromosomes Cancer 37:29-35(2003)


PubMed=12800145; DOI=10.1002/gcc.10218

Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.

A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.

Genes Chromosomes Cancer 37:333-345(2003)


PubMed=15153330; DOI=10.1593/neo.3292; PMCID=PMC1502105

Watts G.S., Oshiro M.M., Junk D.J., Wozniak R.J., Watterson S.J., Domann F.E., Futscher B.W.

The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.

Neoplasia 6:187-194(2004)


PubMed=15677628; DOI=10.1093/carcin/bgi032

Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.

Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.

Carcinogenesis 26:923-930(2005)


PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11.1-11.8(2005)


PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234

Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.

Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

Mol. Cancer Ther. 4:399-412(2005)


PubMed=15900046; DOI=10.1093/jnci/dji133

Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.

p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.

J. Natl. Cancer Inst. 97:765-777(2005)


PubMed=16049480; DOI=10.1038/nature03799; PMCID=PMC1283098

Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W.-P., Giri D.D., Viale A.J., Olshen A.B., Gerald W.L., Massague J.

Genes that mediate breast cancer metastasis to lung.

Nature 436:518-524(2005)


PubMed=16142302; DOI=10.3892/ijo.27.4.881

de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., Remacle J.

Molecular characterization of breast cancer cell lines by a low-density microarray.

Int. J. Oncol. 27:881-892(2005)


PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853

Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.

BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.

Cancer Res. 66:41-45(2006)


PubMed=16417655; DOI=10.1186/bcr1370; PMCID=PMC1413994

Shadeo A., Lam W.L.

Comprehensive copy number profiles of breast cancer cell model genomes.

Breast Cancer Res. 8:R9.1-R9.14(2006)


PubMed=16541312; DOI=10.1007/s10549-006-9186-z

Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.

Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.

Breast Cancer Res. Treat. 99:97-101(2006)


PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miroo T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)


PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008; PMCID=PMC2730521

Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Cancer Cell 10:515-527(2006)


PubMed=17334996; DOI=10.1002/gcc.20438

Jonsson G., Staaf J., Olsson E., Heidenblad M., Vallon-Christersson J., Osoegawa K., de Jong P.J., Oredsson S.M., Ringner M., Hoglund M., Borg A.

High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.

Genes Chromosomes Cancer 46:543-558(2007)


PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004; PMCID=PMC2391005

Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H., Petersen O.W., Gray J.W., Bissell M.J.

The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.

Mol. Oncol. 1:84-96(2007)


PubMed=18277095; DOI=10.4161/cbt.7.5.5712

Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.

Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.

Cancer Biol. Ther. 7:699-708(2008)


PubMed=18386134; DOI=10.1007/s10585-008-9169-z

Hughes L., Malone C., Chumsri S., Burger A.M., McDonnell S.

Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity.

Clin. Exp. Metastasis 25:549-557(2008)


PubMed=18714363; DOI=10.1593/neo.08570; PMCID=PMC2517647

Kischel P., Guillonneau F., Dumont B., Bellahcene A., Stresing V., Clezardin P., De Pauw E.A., Castronovo V.

Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells.

Neoplasia 10:1014-1020(2008)


PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)


PubMed=19582160; DOI=10.1371/journal.pone.0006146; PMCID=PMC2702084

Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

PLoS ONE 4:E6146-E6146(2009)


DOI=10.25904/1912/1434

Morrison B.J.

Breast cancer stem cells: tumourspheres and implications for therapy.

Thesis PhD (2010); Griffith University; Brisbane; Australia


PubMed=19593635; DOI=10.1007/s10549-009-0460-8

Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A.F.A.S., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.

Breast Cancer Res. Treat. 121:53-64(2010)


PubMed=20070913; DOI=10.1186/1471-2407-10-15; PMCID=PMC2836299

Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M., Yamamoto S., Oka M., Hirano T., Sasaki K.

Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.

BMC Cancer 10:15.1-15.10(2010)


PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)


PubMed=21778573; DOI=10.3233/BD-2010-0307; PMCID=PMC3532890

Chavez K.J., Garimella S.V., Lipkowitz S.

Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.

Breast Dis. 32:35-48(2010)


DOI=10.4172/2157-7145.S2-005

Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M.R., Hart R.P., Furtado M.R.

STR profiling of human cell lines: challenges and possible solutions to the growing problem.

J. Forensic Res. 2 Suppl. 2:5-5(2011)


PubMed=21378333

Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I.

Reassessment of estrogen receptor expression in human breast cancer cell lines.

Anticancer Res. 31:521-527(2011)


PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108

Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)


PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017

Kong D.-X., Yamori T.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Bioorg. Med. Chem. 20:1947-1951(2012)


PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

PLoS ONE 7:E31628-E31628(2012)


PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665

Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

PLoS ONE 7:E32096-E32096(2012)


PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)


PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396

Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Cancer Discov. 2:172-189(2012)


PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189

Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Science 336:1040-1044(2012)


PubMed=23151021; DOI=10.1186/1471-2164-13-619; PMCID=PMC3546428

Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.

Molecular characterisation of cell line models for triple-negative breast cancers.

BMC Genomics 13:619.1-619.14(2012)


PubMed=23601657; DOI=10.1186/bcr3415; PMCID=PMC3672661

Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.

miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.

Breast Cancer Res. 15:R33.1-R33.17(2013)


PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)


PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)


PubMed=24009699; DOI=10.1371/journal.pone.0072704; PMCID=PMC3751845

Liu X., Nie H., Zhang Y.-B., Yao Y.-F., Maitikabili A., Qu Y.-P., Shi S.-L., Chen C.-Y., Li Y.

Cell surface-specific N-glycan profiling in breast cancer.

PLoS ONE 8:E72704-E72704(2013)


PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020; PMCID=PMC3931310

Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

Cancer Cell 24:450-465(2013)


PubMed=24162158; DOI=10.1007/s10549-013-2743-3; PMCID=PMC3832776

Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M., Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.

Breast Cancer Res. Treat. 142:237-255(2013)


PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110; PMCID=PMC3937590

Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S., Seth P., Sume V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.

Modeling precision treatment of breast cancer.

Genome Biol. 14:R110.1-R110.14(2013)


PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20.1-20.13(2013)


PubMed=24389870; DOI=10.1038/srep03576; PMCID=PMC3880960

Strauch M., Ludke A., Munch D., Laudes T., Galizia C.G., Martinelli E., Lavra L., Paolesse R., Ulivieri A., Catini A., Capuano R., Di Natale C.

More than apples and oranges -- detecting cancer with a fruit fly's antenna.

Sci. Rep. 4:3576-3576(2014)


PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)


PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)


PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)


PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)


PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050; PMCID=PMC4425736

Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M., Irie H.Y., Lee S.-I., Blau C.A., Villen J.

The proteomic landscape of triple-negative breast cancer.

Cell Rep. 11:630-644(2015)


PubMed=26055192; DOI=10.1021/acs.jproteome.5b00375

Cifani P., Kirik U., Waldemarson S., James P.

Molecular portrait of breast-cancer-derived cell lines reveals poor similarity with tumors.

J. Proteome Res. 14:2819-2827(2015)


PubMed=26218769; DOI=10.1016/j.jchromb.2015.07.021

Willmann L., Schlimpert M., Halbach S., Erbes T., Stickeler E., Kammerer B.

Metabolic profiling of breast cancer: differences in central metabolism between subtypes of breast cancer cell lines.

J. Chromatogr. B 1000:95-104(2015)


PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)


PubMed=26649326; DOI=10.1016/j.dib.2015.09.039; PMCID=PMC4644255

Cox T.R., Schoof E.M., Gartland A., Erler J.T., Linding R.

Dataset for the proteomic inventory and quantitative analysis of the breast cancer hypoxic secretome associated with osteotropism.

Data Brief 5:621-625(2015)


PubMed=27331101; DOI=10.1016/j.dib.2016.05.040; PMCID=PMC4905937

Aumsuwan P., Khan S.I., Khan I.A., Walker L.A., Dasmahapatra A.K.

Gene expression profiling and pathway analysis data in MCF-7 and MDA-MB-231 human breast cancer cell lines treated with dioscin.

Data Brief 8:272-279(2016)


PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877

Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Sci. Data 3:160052-160052(2016)


PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)


PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20.1-20.11(2016)


PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)


PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470; PMCID=PMC5557415

Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.

Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.

J. Proteome Res. 16:1391-1400(2017)


PubMed=28889351; DOI=10.1007/s10549-017-4496-x

Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.

Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.

Breast Cancer Res. Treat. 167:289-301(2018)


PubMed=29273624; DOI=10.1101/gr.226019.117; PMCID=PMC5793780

Franco H.L., Nagari A., Malladi V.S., Li W.-Q., Xi Y.-X., Richardson D., Allton K.L., Tanaka K., Li J., Murakami S., Keyomarsi K., Bedford M.T., Shi X.-B., Li W., Barton M.C., Dent S.Y.R., Kraus W.L.

Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.

Genome Res. 28:159-170(2018)


PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)


PubMed=30971826; DOI=10.1038/s41586-019-1103-9

Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Nature 568:511-516(2019)


PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)


PubMed=31092827; DOI=10.1038/s41467-019-10148-6; PMCID=PMC6520398

Liu K., Newbury P.A., Glicksberg B.S., Zeng W.Z.-D., Paithankar S., Andrechek E.R., Chen B.

Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data.

Nat. Commun. 10:2138.1-2138.12(2019)


PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402.e16(2020)


PubMed=32782317; DOI=10.1038/s41598-020-70393-4; PMCID=PMC7419295

Risha Y., Minic Z., Ghobadloo S.M., Berezovski M.V.

The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers.

Sci. Rep. 10:13572-13572(2020)


PubMed=34238275; DOI=10.1186/s12885-021-08511-2; PMCID=PMC8268371

Samson J., Derlipanska M., Zaheed O., Dean K.

Molecular and cellular characterization of two patient-derived ductal carcinoma in situ (DCIS) cell lines, ETCC-006 and ETCC-010.

BMC Cancer 21:790.1-790.20(2021)"




關(guān)鍵字: MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇;傳代細(xì)胞;復(fù)蘇細(xì)胞;實驗細(xì)胞;科研細(xì)胞;

公司簡介

上海冠導(dǎo)生物工程有限公司,先后從ATCC、DSMZ、ECACC、RIKEN、PromoCell、ScienCell、JCRB等國內(nèi)外細(xì)胞庫引進(jìn)細(xì)胞2000余株。以此為契機(jī),公司組建了冠導(dǎo)細(xì)胞庫,我司細(xì)胞均由資深細(xì)胞培養(yǎng)工程師進(jìn)行培養(yǎng)。我司可以提供的細(xì)胞有:①細(xì)胞系②原代細(xì)胞③穩(wěn)轉(zhuǎn)株④耐藥株⑤標(biāo)記細(xì)胞⑥細(xì)胞配套試劑等。
成立日期 2015-11-05 (10年) 注冊資本 100萬(元)
員工人數(shù) 50-100人 年營業(yè)額 ¥ 1000萬-5000萬
主營行業(yè) 細(xì)胞培養(yǎng),微生物學(xué),細(xì)胞生物學(xué) 經(jīng)營模式 工廠,試劑,定制,服務(wù)
  • 上海冠導(dǎo)生物工程有限公司
VIP 4年
  • 公司成立:10年
  • 注冊資本:100萬(元)
  • 企業(yè)類型:有限責(zé)任公司(自然人投資或控股)
  • 主營產(chǎn)品:①細(xì)胞系②原代細(xì)胞③穩(wěn)轉(zhuǎn)株④耐藥株⑤標(biāo)記細(xì)胞⑥細(xì)胞配套試劑等。
  • 公司地址:手機(jī)號/微信號:18818239863 【QQ號:3171921642】上海市張江高科技園區(qū)
詢盤

MDA-MB-231人乳腺癌細(xì)胞全年復(fù)蘇|已有STR圖譜相關(guān)廠家報價

更多
產(chǎn)品名稱 價格   公司名稱 報價日期
詢價
VIP1年
上海賓穗生物科技有限公司
2025-04-05
詢價
VIP6年
上海弘順生物科技有限公司
2025-04-05
詢價
VIP5年
上海賓穗生物科技有限公司
2025-04-05
¥1500
VIP4年
上海雅吉生物科技有限公司
2025-04-04
¥1500
VIP1年
上海晶風(fēng)生物科技有限公司
2025-04-04
¥10000
VIP4年
吉奧藍(lán)圖(廣東)生命科學(xué)技術(shù)中心
2025-04-03
¥1500
VIP3年
上海滬震實業(yè)有限公司
2025-04-03
¥1480
武漢尚恩生物技術(shù)有限公司
2023-12-18
詢價
VIP1年
上海賓穗生物科技有限公司
2025-04-05
詢價
VIP5年
上海賓穗生物科技有限公司
2025-04-05
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價格指該商品的參考價格,并非原價,該價格可能隨著市場變化,或是由于您購買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價格,請咨詢商家,以實際成交價格為準(zhǔn)。請意識到互聯(lián)網(wǎng)交易中的風(fēng)險是客觀存在的